Assessing NovoCure: Insights From 4 Financial Analysts
Analysts' ratings for NovoCure (NASDAQ:NVCR) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.5, a high estimate of $42.00, and a low estimate of $18.00. This current average represents a 0.81% decrease from the previous average price target of $30.75.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of NovoCure by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Nierengarten | Wedbush | Maintains | Neutral | $18.00 | $18.00 |
| Emily Bodnar | HC Wainwright & Co. | Lowers | Buy | $39.00 | $42.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $42.00 | $38.00 |
| Jessica Fye | JP Morgan | Lowers | Neutral | $23.00 | $25.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NovoCure. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NovoCure compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NovoCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on NovoCure analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Understanding the Numbers: NovoCure's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, NovoCure showcased positive performance, achieving a revenue growth rate of 7.81% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NovoCure's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -22.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): NovoCure's ROE excels beyond industry benchmarks, reaching -10.79%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): NovoCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.86%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: NovoCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 2.34.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.